SourceBio International (LON: SBI) should be publishing a trading update in the near future. The AIM-quoted diagnostics and testing company was hit by downgrades last year because of lower Covid PCR testing levels, but the emergence of Omicron has boosted demand.
The share price has recovered in the past two months, although it is still lower than one year ago. At 157.5p a share, SourceBio International is valued at £116.8m.
There should be guidance on the outcome of 2021 but more importantly there should be an indication of expectations for 2022. Last year’s figures could be slightly b...
